NCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
Clinical Trials
27 trialsNCT06994299 2025-11-18
PRISM
Weill Medical College of Cornell University
Phase 2 Withdrawn
NCT05358691 2025-04-16
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Rutgers, The State University of New Jersey
Phase 1 Withdrawn
NCT04889066 2024-12-20
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT03802747 2024-12-09
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
University of Colorado, Denver
Phase 1 Withdrawn
NCT05757843 2024-09-19
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
Indiana University
Phase 2 Withdrawn
NCT04944173 2024-09-03
SCION
University of British Columbia
Phase 2 Withdrawn
NCT05572476 2024-06-05
LURBIMUNE
Institut Bergonié
Phase 2 Withdrawn
NCT05848843 2024-01-23
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05161533 2023-10-18
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
University of Washington
Phase 2 Withdrawn
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT05383001 2022-09-27
Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
AIO-Studien-gGmbH
Phase 2 Withdrawn
NCT04001413 2022-07-29
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT04223648 2021-11-22
Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma
Yale University
Phase EARLY_PHASE1 Withdrawn
NCT04262375 2020-11-17
DOMINATION
University Health Network, Toronto
Phase 2 Withdrawn
NCT04262388 2020-11-17
DOME
University Health Network, Toronto
Phase 2 Withdrawn
NCT04088032 2020-07-16
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
Stony Brook University
Phase EARLY_PHASE1 Withdrawn
NCT04073160 2020-07-07
TRIO Bladder
Duke University
Phase 1 Withdrawn
NCT04184518 2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2 Withdrawn
NCT02885727 2019-09-12
Panc-Durval+RT
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT02871323 2019-08-20
Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Northwestern University
Phase 1 Withdrawn
NCT02868632 2019-04-05
Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
NYU Langone Health
Phase 1 Withdrawn
NCT03241017 2018-04-09
IDA-D
Insel Gruppe AG, University Hospital Bern
Phase 2 Withdrawn
NCT03004105 2018-03-16
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03235869 2018-03-15
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT02966587 2018-01-17
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Washington
Phase 2 Withdrawn
NCT02993991 2017-12-29
PRIMED-001
University Health Network, Toronto
Phase 1 Withdrawn